about
Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics.The interval between a single course of antenatal steroids and delivery and its association with neonatal outcomes.Characteristics of Real-Time, Non-Critical Incident Debriefing Practices in the Emergency Department.ACMG statement on noninvasive prenatal screening for fetal aneuploidy.The genetics of diabetic pregnancy.Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results.Patient Perspectives on Intimate Partner Violence Discussion during Genetic Counseling Sessions.Frequency of fetal karyotype abnormalities in women undergoing invasive testing in the absence of ultrasound and other high-risk indications.Challenges of Pre- and Post-Test Counseling for Orthodox Jewish Individuals in the Premarital Phase.Carrier Screening: Past, Present, and Future.The type of feto-placental aneuploidy detected by cfDNA testing may influence the choice of confirmatory diagnostic procedure.Implications of fetoplacental mosaicism on cell-free DNA testing for sex chromosome aneuploidies.Genetic Counselors' Perception of the Effect on Practice of Laws Restricting Abortion.The PEARLS Healthcare Debriefing Tool."No-Go Considerations" for In Situ Simulation Safety.Validating Obstetric Emergency Checklists using Simulation: A Randomized Controlled Trial.Rapid and novel prenatal molecular assay for detecting aneuploidies and microdeletion syndromesClinical utility of chromosomal microarray analysis in prenatal diagnosis: report of first 6 months in clinical practiceThe Integration of Noninvasive Prenatal Screening into the Existing Prenatal Paradigm: a Survey of Current Genetic Counseling PracticeRevisiting the challenges of training Maternal Fetal Medicine fellows in chorionic villus samplingConnecting simulation and quality improvement: how can healthcare simulation really improve patient care?Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA
P50
Q34535626-D6442841-FC78-4B28-B5FD-81E31F9602E2Q36255456-7FB4B3F9-8C4F-49B6-8D32-183E31B4626BQ37580607-7287815C-125D-4BC3-9CF2-2486E4F0B5E7Q38096182-9352DE26-71BF-497E-8133-8BE026F6DE41Q38273458-2909ADDC-472D-4EA0-96AE-3B27EB997B88Q39024055-F23BC51A-6FE0-4E00-9B83-7EFBE7AA45C5Q40427609-BF0FC1FD-5717-45DE-B04A-EE35EE0B2469Q40524568-849A8764-04B1-4B44-8066-5A656369CC26Q41382663-0025479E-C610-43D5-9855-001DD24ADBF9Q46330110-03545A4B-4515-40FC-BF8B-2F6309316919Q48154335-5F4A2959-FBB8-40D6-BBA1-2B00D7E90C22Q48249497-3A357F1F-5352-4837-A742-0EE7B5DB3CF5Q48353683-F54C6D95-A952-4876-829E-1F27DE8EE7C2Q49579542-61A53B1D-A6C9-4E4E-966D-6D37787D6B69Q52604749-53D637C7-0FA9-461C-916E-038AD3FE663FQ53587709-D2813828-1961-41B4-86FF-36C5E9453DDEQ83131556-9FEB427F-2DC0-418E-8F49-A53EDCDB7AD3Q86568879-95A30B5A-E5D5-4DBE-A21B-3BE94F34D883Q87298407-DB39B1A3-B2E3-4CC2-BC82-E978793F180EQ88139702-734C1CCF-9380-4B20-BAA6-871D1E4F80D0Q92001534-E0A9D02A-E190-44B1-9432-C95D4FDF3E5AQ95437491-1337783F-66DC-4111-B245-46D3DD3F5B16
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-0942-3021
@en
name
Komal Bajaj
@ast
Komal Bajaj
@en
Komal Bajaj
@es
Komal Bajaj
@nl
type
label
Komal Bajaj
@ast
Komal Bajaj
@en
Komal Bajaj
@es
Komal Bajaj
@nl
prefLabel
Komal Bajaj
@ast
Komal Bajaj
@en
Komal Bajaj
@es
Komal Bajaj
@nl
P106
P1153
36945037300
P31
P496
0000-0002-0942-3021